Muscular Dystrophy Drug

    This image provided by Sarepta Therapeutics in December 2019 shows a box and vial of their drug Vyondys
    53. On Thursday, Dec. 12, 2019, U.S. health regulators said they approved this second drug for a
    debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for
    safety concerns just four months earlier.